CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Cefdinir

头孢地尼 杂质对照品Cefdinir Impurities

ChP37 个杂质条目37 impurity entries

本页汇总 头孢地尼 的 37 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 37 impurity reference standards of Cefdinir with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 头孢地尼(Cefdinir)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsStability Indicating RP-HPLC and Spectrophotometric Methods for Simultaneous Estimation of Sodium Benzoate and Cefdinir in the Presence of its Degradation Products-Application to Blank Subtraction Method
    Turkish journal of pharmaceutical sciences · 2022 · Mohamed MA, Hassouna MEM  ·  PMID 36317873  ·  DOI
  2. 分析方法Analytical MethodsA developed and validated stability-indicating reverse-phase high performance liquid chromatographic method for determination of cefdinir in the presence of its degradation products as per International Conference on Harmonization guidelines
    Pharmaceutical methods · 2011 · Hamrapurkar P et al.  ·  PMID 23781424  ·  DOI
  3. 分析方法Analytical MethodsMethod development for the determination of cefdinir and its related substances by high-performance liquid chromatography
    Journal of pharmaceutical and biomedical analysis · 1996 · Okamoto Y et al.  ·  PMID 8807549  ·  DOI
  4. 分析方法Analytical MethodsSimultaneous determination of cefdinir and cefixime in human plasma by RP-HPLC/UV detection method: Method development, optimization, validation, and its application to a pharmacokinetic study
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2011 · Khan A et al.  ·  PMID 21782531  ·  DOI
  5. 分析方法Analytical Methods[Construction of the quantitative structure retention relationship of cefdinir related substances]
    Yao xue xue bao = Acta pharmaceutica Sinica · 2015 · Wang C et al.  ·  PMID 26757554

头孢地尼 —— 原料药与杂质对照品Cefdinir — drug substance & impurities

共 38 个条目(含原料药本体)38 items incl. the drug substance
Cefdinir structure
ChP原料药 APIAPI
头孢地尼Cefdinir
Cefdinir
CAS No.91832-40-5
Chemical FormulaC14H13N5O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 15 (Cefdinir ChP Impurity A) structure
ChPA
头孢地尼杂质15 (头孢地尼ChP杂质A)Cefdinir Impurity 15 (Cefdinir ChP Impurity A)
Cefdinir Impurity 15 (Cefdinir ChP Impurity A)
CAS No.1450758-21-0
Chemical FormulaC5H6N4O2S
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 30 (Cefdinir ChP Impurity C) structure
ChPC
头孢地尼杂质30 (头孢地尼ChP杂质C)Cefdinir Impurity 30 (Cefdinir ChP Impurity C)
Cefdinir Impurity 30 (Cefdinir ChP Impurity C)
CAS No.79349-82-9
Chemical FormulaC9H10N2O3S
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 9 (Cefdinir ChP Impurity D) structure
ChPD
头孢地尼杂质9 (头孢地尼ChP杂质D)Cefdinir Impurity 9 (Cefdinir ChP Impurity D)
Cefdinir Impurity 9 (Cefdinir ChP Impurity D)
CAS No.934986-48-8
Chemical FormulaC14H13N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 2 (Cefdinir ChP Impurity F) structure
ChPF
头孢地尼杂质2 (头孢地尼ChP杂质F)Cefdinir Impurity 2 (Cefdinir ChP Impurity F)
Cefdinir Impurity 2 (Cefdinir ChP Impurity F)
CAS No.934986-49-9
Chemical FormulaC14H13N5O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 1 Sodium Salt (3-Methyl Cefdinir Sodium Salt) (Cefdinir ChP Impurity G Sodium Salt) structure
ChPG
头孢地尼杂质1 钠盐 (3-甲基头孢地尼钠盐) (头孢地尼ChP杂质G 钠盐)Cefdinir Impurity 1 Sodium Salt (3-Methyl Cefdinir Sodium Salt) (Cefdinir ChP Impurity G Sodium Salt)
Cefdinir Impurity 1 Sodium Salt (3-Methyl Cefdinir Sodium Salt) (Cefdinir ChP Impurity G Sodium Salt)
CAS No.66436-47-3
Chemical FormulaC13H12N5O5S2-·Na+
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 1(3-Methyl Cefdinir) (Cefdinir ChP Impurity G) structure
ChPG
头孢地尼杂质1 (3-甲基头孢地尼) (头孢地尼ChP杂质G)Cefdinir Impurity 1(3-Methyl Cefdinir) (Cefdinir ChP Impurity G)
Cefdinir Impurity 1(3-Methyl Cefdinir) (Cefdinir ChP Impurity G)
CAS No.71091-93-5
Chemical FormulaC13H13N5O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 23 (Cefdinir ChP Impurity I) structure
ChPI
头孢地尼杂质23 (头孢地尼ChP杂质I)Cefdinir Impurity 23 (Cefdinir ChP Impurity I)
Cefdinir Impurity 23 (Cefdinir ChP Impurity I)
CAS No.1450758-22-1
Chemical FormulaC14H15N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 24 (Cefdinir ChP Impurity J) structure
ChPJ
头孢地尼杂质24 (头孢地尼ChP杂质J)Cefdinir Impurity 24 (Cefdinir ChP Impurity J)
Cefdinir Impurity 24 (Cefdinir ChP Impurity J)
CAS No.1450758-23-2
Chemical FormulaC14H15N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 21 (Cefdinir ChP Impurity K) structure
ChPK
头孢地尼杂质21 (头孢地尼ChP杂质K)Cefdinir Impurity 21 (Cefdinir ChP Impurity K)
Cefdinir Impurity 21 (Cefdinir ChP Impurity K)
CAS No.178422-45-2
Chemical FormulaC14H15N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 22 (Cefdinir ChP Impurity L) structure
ChPL
头孢地尼杂质22 (头孢地尼ChP杂质L)Cefdinir Impurity 22 (Cefdinir ChP Impurity L)
Cefdinir Impurity 22 (Cefdinir ChP Impurity L)
CAS No.1450758-24-3
Chemical FormulaC14H15N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 13 (Cefdinir ChP Impurity M) structure
ChPM
头孢地尼杂质13 (头孢地尼ChP杂质M)Cefdinir Impurity 13 (Cefdinir ChP Impurity M)
Cefdinir Impurity 13 (Cefdinir ChP Impurity M)
CAS No.946573-41-7
Chemical FormulaC14H13N5O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 4 (Cefdinir ChP Impurity N) structure
ChPN
头孢地尼杂质4 (头孢地尼ChP杂质N)Cefdinir Impurity 4 (Cefdinir ChP Impurity N)
Cefdinir Impurity 4 (Cefdinir ChP Impurity N)
CAS No.178601-89-3
Chemical FormulaC14H13N5O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 14 (Cefdinir ChP Impurity O) structure
ChPO
头孢地尼杂质14 (头孢地尼ChP杂质O)Cefdinir Impurity 14 (Cefdinir ChP Impurity O)
Cefdinir Impurity 14 (Cefdinir ChP Impurity O)
CAS No.79350-10-0
Chemical FormulaC14H14N4O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 19 (Cefdinir ChP Impurity P) structure
ChPP
头孢地尼杂质19 (头孢地尼ChP杂质P)Cefdinir Impurity 19 (Cefdinir ChP Impurity P)
Cefdinir Impurity 19 (Cefdinir ChP Impurity P)
CAS No.2135796-40-4
Chemical FormulaC14H15N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 20 (Cefdinir ChP Impurity Q) structure
ChPQ
头孢地尼杂质20 (头孢地尼ChP杂质Q)Cefdinir Impurity 20 (Cefdinir ChP Impurity Q)
Cefdinir Impurity 20 (Cefdinir ChP Impurity Q)
CAS No.2135796-41-5
Chemical FormulaC14H15N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 5 (Cefdinir ChP Impurity R) structure
ChPR
头孢地尼杂质5 (头孢地尼ChP杂质R)Cefdinir Impurity 5 (Cefdinir ChP Impurity R)
Cefdinir Impurity 5 (Cefdinir ChP Impurity R)
CAS No.178601-88-2
Chemical FormulaC14H13N5O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 18 (Cefdinir ChP Impurity S) structure
ChPS
头孢地尼杂质18 (头孢地尼ChP杂质S)Cefdinir Impurity 18 (Cefdinir ChP Impurity S)
Cefdinir Impurity 18 (Cefdinir ChP Impurity S)
CAS No.127770-93-8
Chemical FormulaC16H15N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 26 (Cefdinir ChP Impurity U) structure
ChPU
头孢地尼杂质26 (头孢地尼ChP杂质U)Cefdinir Impurity 26 (Cefdinir ChP Impurity U)
Cefdinir Impurity 26 (Cefdinir ChP Impurity U)
CAS No.178422-43-0
Chemical FormulaC13H15N5O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 6 (Mixture of Diastereomers) structure
6
头孢地尼杂质6(非对映异构体混合物)Cefdinir Impurity 6 (Mixture of Diastereomers)
Cefdinir Impurity 6 (Mixture of Diastereomers)
CAS No.178949-04-7
Chemical FormulaC13H15N5O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 7 structure
7
头孢地尼杂质7Cefdinir Impurity 7
Cefdinir Impurity 7
CAS No.178422-40-7
Chemical FormulaC7H10N4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 8 structure
8
头孢地尼杂质8Cefdinir Impurity 8
Cefdinir Impurity 8
CAS No.178949-03-6
Chemical FormulaC7H8N4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 11 structure
11
头孢地尼杂质11Cefdinir Impurity 11
Cefdinir Impurity 11
CAS No.1356842-10-8
Chemical FormulaC13H11N3O6S
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 12 structure
12
头孢地尼杂质12Cefdinir Impurity 12
Cefdinir Impurity 12
CAS No.79350-14-4
Chemical FormulaC14H12N4O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 34 structure
34
头孢地尼杂质34Cefdinir Impurity 34
Cefdinir Impurity 34
CAS No.130696-95-6
Chemical FormulaC48H40IN5O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 35 structure
35
头孢地尼杂质35Cefdinir Impurity 35
Cefdinir Impurity 35
CAS No.104797-47-9
Chemical FormulaC14H10N4O3S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 38 structure
38
头孢地尼杂质38Cefdinir Impurity 38
Cefdinir Impurity 38
CAS No.1269661-24-6
Chemical FormulaC24H22Cl2N2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 39 structure
39
头孢地尼杂质39Cefdinir Impurity 39
Cefdinir Impurity 39
CAS No.104146-10-3
Chemical FormulaC24H23ClN2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 41 structure
41
头孢地尼杂质41Cefdinir Impurity 41
Cefdinir Impurity 41
CAS No.1269661-23-5
Chemical FormulaC24H23ClN2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 42 structure
42
头孢地尼杂质42Cefdinir Impurity 42
Cefdinir Impurity 42
CAS No.29126-11-2
Chemical FormulaC24H24N2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 46 structure
46
头孢地尼杂质46Cefdinir Impurity 46
Cefdinir Impurity 46
CAS No.66340-40-7
Chemical FormulaC6H8BrNO4
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 47 structure
47
头孢地尼杂质47Cefdinir Impurity 47
Cefdinir Impurity 47
CAS No.60845-81-0
Chemical FormulaC7H9N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 48 structure
48
头孢地尼杂质48Cefdinir Impurity 48
Cefdinir Impurity 48
CAS No.75689-07-5
Chemical FormulaC6H8BrNO4
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 49 structure
49
头孢地尼杂质49Cefdinir Impurity 49
Cefdinir Impurity 49
CAS No.66340-85-0
Chemical FormulaC6H8BrNO4
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 50 structure
50
头孢地尼杂质50Cefdinir Impurity 50
Cefdinir Impurity 50
CAS No.2408157-08-2
Chemical FormulaC28H24N10O9S4
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 52 structure
52
头孢地尼杂质52Cefdinir Impurity 52
Cefdinir Impurity 52
CAS No.178422-39-4
Chemical FormulaC14H15N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 58 structure
58
头孢地尼杂质58Cefdinir Impurity 58
Cefdinir Impurity 58
CAS No.1330164-22-1
Chemical FormulaC13H11N3O6S
Purity>95%询价On request
10mg25mg50mg100mg
Cefdinir Impurity 59 structure
59
头孢地尼杂质59Cefdinir Impurity 59
Cefdinir Impurity 59
CAS No.178422-42-9
Chemical FormulaC14H15N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

头孢地尼 —— 研究文献与合成路线Cefdinir — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 头孢地尼 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Cefdinir. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Stability Indicating RP-HPLC and Spectrophotometric Methods for Simultaneous Estimation of Sodium Benzoate and Cefdinir in the Presence of its Degradation Products-Application to Blank Subtraction Method
    Mohamed MA, Hassouna MEM · Turkish journal of pharmaceutical sciences · 2022 · 被引 4cited 4
  2. A developed and validated stability-indicating reverse-phase high performance liquid chromatographic method for determination of cefdinir in the presence of its degradation products as per International Conference on Harmonization guidelines
    Hamrapurkar P, Patil P, Phale M, et al. · Pharmaceutical methods · 2011 · 被引 4cited 4
  3. Isolation, structural elucidation and characterization of impurities in Cefdinir
    Rao KV, Rani A, Reddy AV, et al. · Journal of pharmaceutical and biomedical analysis · 2007 · 被引 12cited 12
  4. Spectophotometric methods for determination of cefdinir in pharmaceutical formulations via derivatization with 1,2-naphthoquinone-4-sulfonate and 4-chloro-7-nitrobenzo-2-oxa-1, 3-diazole
    Gouda AA, Hashem H, Hassan W · Drug testing and analysis · 2012 · 被引 5cited 5

合成与制备工艺专利Synthesis & process patents

  1. INTERMEDIATES USEFUL FOR SYNTHESIZING CEFDINIR, AND PROCESS FOR PREPARING CEFDINIR USING THE SAME
    KIM SEONG HO, SONG YOON SEOK, LEE SEUNG JAE, KIM HUNG SOP, et al. · 公开号 KR20090106268KR20090106268 · 2009
  2. Cefdinir synthesis process
    ANTONIO MANCA, MAURO FILIPPI, MAURIZIO SALA BRUNO, AMBROGIO MONGUZZI RICCARDO, et al. · 公开号 ZA200806049ZA200806049 · 2009
  3. CEFDINIR synthesis process
    MANCA ANTONIO, FILIPPI MAURO, SALA BRUNO MAURIZIO, MONGUZZI RICCARDO AMBROGIO, et al. · 公开号 EP2030975EP2030975 · 2009
  4. CEFDINIR SYNTHESIS PROCESS
    MANCA ANTONIO, FILIPPI MAURO, SALA BRUNO MAURIZIO, MONGUZZI RICCARDO AMBROGIO, et al. · 公开号 KR20090014985KR20090014985 · 2009
  5. PROCESS FOR THE PREPARATION OF CEFDINIR
    KANSAL VINOD KUMAR, MISTRY DHIRENKUMAR N, PANDEY SAURABH, PATEL RAKESH, et al. · 公开号 KR20080064990KR20080064990 · 2008

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

头孢地尼 杂质谱研究要点Cefdinir — impurity profiling notes

下面这些是拿到 头孢地尼 的 38 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 38 impurity entries for Cefdinir, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances